Review 10.1172/JCI129338
1Centre for Cancer Therapeutics, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada.
2Department of Biochemistry, Microbiology and Immunology, and
3Department of Surgery, University of Ottawa, Ottawa, Ontario, Canada.
Address correspondence to: Michele Ardolino, 501 Smyth Road, Cancer Center, 3-328, Ottawa, Ontario K1H8M2, Canada. Phone: 613.737.8899 ext. 77257; Email: m.ardolino@uottawa.ca.
Authorship note: JJH and STK equally contributed to this manuscript.
Find articles by
Hodgins, J.
in:
JCI
|
PubMed
|
Google Scholar
|
1Centre for Cancer Therapeutics, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada.
2Department of Biochemistry, Microbiology and Immunology, and
3Department of Surgery, University of Ottawa, Ottawa, Ontario, Canada.
Address correspondence to: Michele Ardolino, 501 Smyth Road, Cancer Center, 3-328, Ottawa, Ontario K1H8M2, Canada. Phone: 613.737.8899 ext. 77257; Email: m.ardolino@uottawa.ca.
Authorship note: JJH and STK equally contributed to this manuscript.
Find articles by Khan, S. in: JCI | PubMed | Google Scholar
1Centre for Cancer Therapeutics, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada.
2Department of Biochemistry, Microbiology and Immunology, and
3Department of Surgery, University of Ottawa, Ottawa, Ontario, Canada.
Address correspondence to: Michele Ardolino, 501 Smyth Road, Cancer Center, 3-328, Ottawa, Ontario K1H8M2, Canada. Phone: 613.737.8899 ext. 77257; Email: m.ardolino@uottawa.ca.
Authorship note: JJH and STK equally contributed to this manuscript.
Find articles by Park, M. in: JCI | PubMed | Google Scholar
1Centre for Cancer Therapeutics, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada.
2Department of Biochemistry, Microbiology and Immunology, and
3Department of Surgery, University of Ottawa, Ottawa, Ontario, Canada.
Address correspondence to: Michele Ardolino, 501 Smyth Road, Cancer Center, 3-328, Ottawa, Ontario K1H8M2, Canada. Phone: 613.737.8899 ext. 77257; Email: m.ardolino@uottawa.ca.
Authorship note: JJH and STK equally contributed to this manuscript.
Find articles by
Auer, R.
in:
JCI
|
PubMed
|
Google Scholar
|
1Centre for Cancer Therapeutics, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada.
2Department of Biochemistry, Microbiology and Immunology, and
3Department of Surgery, University of Ottawa, Ottawa, Ontario, Canada.
Address correspondence to: Michele Ardolino, 501 Smyth Road, Cancer Center, 3-328, Ottawa, Ontario K1H8M2, Canada. Phone: 613.737.8899 ext. 77257; Email: m.ardolino@uottawa.ca.
Authorship note: JJH and STK equally contributed to this manuscript.
Find articles by
Ardolino, M.
in:
JCI
|
PubMed
|
Google Scholar
|
First published September 3, 2019 - More info
Natural killer (NK) cells are innate cytotoxic lymphocytes involved in the surveillance and elimination of cancer. As we have learned more and more about the mechanisms NK cells employ to recognize and eliminate tumor cells, and how, in turn, cancer evades NK cell responses, we have gained a clear appreciation that NK cells can be harnessed in cancer immunotherapy. Here, we review the evidence for NK cells’ critical role in combating transformed and malignant cells, and how cancer immunotherapies potentiate NK cell responses for therapeutic purposes. We highlight cutting-edge immunotherapeutic strategies in preclinical and clinical development such as adoptive NK cell transfer, chimeric antigen receptor–expressing NK cells (CAR-NKs), bispecific and trispecific killer cell engagers (BiKEs and TriKEs), checkpoint blockade, and oncolytic virotherapy. Further, we describe the challenges that NK cells face (e.g., postsurgical dysfunction) that must be overcome by these therapeutic modalities to achieve cancer clearance.
A subscription is required for you to read this article in full. If you are a subscriber, you may sign in to continue reading.
Click here to sign into your account.
Please select one of the subscription options, which includes a low-cost option just for this article.
If you are at an institution or library and believe you should have access, please check with your librarian or administrator (more information).
Please try these troubleshooting tips.